Showing 131 - 140 of 1,665
Robert S. Pindyck has made significant contributions to a wide and diverse range of economic literatures; summarizing them is challenging. To keep the length of this review manageable, I confine my discussion to four areas in which his contributions have been particularly notable: (i) economic...
Persistent link: https://www.econbiz.de/10014359439
Persistent link: https://www.econbiz.de/10009925544
Estimating the value of medical innovation is a continual challenge. In this research, we quantify the impact of antihypertensive therapy on U.S. blood pressures, risk and number of heart attacks, strokes, and deaths. We also consider the potential for further improvements. We estimate the value...
Persistent link: https://www.econbiz.de/10005829656
The success of deregulation in creating a viable private rail freight system in the ?U.S. since 1979 is relatively undisputed. Deregulation has proceeded in three ways: (i) eased rate setting restrictions; (ii) simplified merger applications and approval procedures; and (iii) relaxed route...
Persistent link: https://www.econbiz.de/10005829912
<DIV><DIV><DIV><P>The celebrated economist Zvi Griliches’s entire career can be viewed as an attempt to advance the cause of accuracy in economic measurement. His interest in the causes and consequences of technical progress led to his pathbreaking work on price hedonics, now the principal analytical technique...</p></div></div></div>
Persistent link: https://www.econbiz.de/10011156053
<DIV><DIV><P>This volume contains papers presented at a conference in May 1988 in Washington, D.C., commemorating the fiftieth anniversary of the founding of the Conference on Research in Income and Wealth (CRIW). The call for papers emphasized assessments of broad topics in economic measurement, both...</p></div></div>
Persistent link: https://www.econbiz.de/10011156056
<DIV>With the United States and other developed nations spending as much as 14 percent of their GDP on medical care, economists and policy analysts are asking what these countries are getting in return. Yet it remains frustrating and difficult to measure the productivity of the medical care service...</div>
Persistent link: https://www.econbiz.de/10011156201
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the...
Persistent link: https://www.econbiz.de/10011156823
Physicians prescribing drugs for patients with schizophrenia and related conditions are remarkably concentrated in their choice among antipsychotic drugs. In 2007 the single antipsychotic drug prescribed by a physician accounted for 66% of all antipsychotic prescriptions written by that...
Persistent link: https://www.econbiz.de/10008855519
The pricing of medical products and services in the U.S. is notoriously complex. In health care, supply prices (those received by the manufacturer) are distinct from demand prices (those paid by the patient) due to health insurance. The insurer, in designing the benefit, decides what prices...
Persistent link: https://www.econbiz.de/10008868165